Although research is being conducted on Long COVID or Long COVID-19, whose symptoms continue for weeks and months after initial infection, there are very few ongoing clinical trials on treatments. Anecdotally, there has been what appears to be a successful treatment for Long Covid using Pfizer’s antiviral regimen Paxlovid.
U.S. FDA Advisers to Discuss Additional COVID Vaccine BoostersBNT162b2 (Pfizer and BioNTech), Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Reinfections, COVID-19 booster shots, COVID-19 shots, COVID-19 Vaccines, FDA, FDA Statements, FDA/Regulatory, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Omicron (B.1.1.529) (South Africa), Research & Development, Therapeutics, Vaccines
The U.S. Food and Drug Administration’s expert advisers will discuss the timing of additional COVID-19 vaccine boosters and the people eligible for the extra shots in a meeting later this week, the health agency said on April 4.
Explainer: Omicron ‘stealth’ COVID variant BA.2 now dominant globallyAsia, China, Coronavirus Disease 2019 (COVID-19) Reinfections, COVID-19 transmission, COVID-19 Vaccinations, Europe, Germany, Omicron (B.1.1.529) (South Africa), Omicron BA.2, Public Health Crisis, R&D, Scientists, United Kingdom, United States
A sub-variant of the highly transmissible Omicron version of coronavirus known as BA.2 is now dominant worldwide, prompting surges in many countries in Europe and Asia and raising concern over the potential for a new wave in the United States.
Prior COVID offers less protection vs Omicron; mRNA booster shot efficacy declines within monthsBNT162b2 (Pfizer and BioNTech), CDC, Clinical Data, Coronavirus Disease 2019 (COVID-19) Reinfections, COVID-19 booster shots, Covid-19 Data, COVID-19 shots, COVID-19 Vaccines, Hospitalized COVID-19 Patients, Immune Response, Messenger RNA (mRNA) Vaccines, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), New England Journal of Medicine, Omicron (B.1.1.529) (South Africa), Omicron BA.2, R&D
The immune response to COVID-19 helps protect against reinfection, but that protection is weaker against Omicron than it was against earlier variants of the coronavirus, according to new data. In other news, protection provided by booster shots of the mRNA vaccines from Moderna Inc. or Pfizer Inc. and partner BioNTech SE starts waning quickly, according to data published in Feb. 11th’s Morbidity and Mortality Weekly Report from the U.S. Centers for Disease Control and Prevention (CDC).
The Omicron variant of the coronavirus is spreading faster than the Delta variant and is causing infections in people already vaccinated or who have recovered from the Covid-19 disease, the head of the World Health Organization (WHO) said on December 20.
The risk of reinfection with the Omicron coronavirus variant is more than five times higher and it has shown no sign of being milder than Delta, a study showed, as cases soar across Europe and threaten year-end festivities.
Survivors of previous infection with the virus that causes SARS-CoV-2 may be at higher risk for reinfection with the Omicron variant than with earlier versions of the virus, preliminary findings show. Additionally, a booster shot of the Pfizer/BioNTech Covid-19 vaccine appears to provide strong protection – at least in the short term – according to data from Israel.
The inexpensive antidepressant fluvoxamine might help keep patients with Covid-19 from developing severe disease, according to a study published in The Lancet Global Health. Researchers found in another study that the coronavirus can infect cells of the inner ear, which may help explain the balance problems, hearing loss and tinnitus (ringing in the ears) experienced by some Covid-19 patients.
Coronavirus cases worldwide surpassed 200 million on Aug. 4, according to a Reuters tally, as the more-infectious Delta variant threatens areas with low vaccination rates and strains healthcare systems.
Pfizer, BioNTech to seek authorization for Covid booster shot as Delta variant spreadsBioNTech, BNT162b2 (Pfizer and BioNTech), CDC, Coronavirus Disease 2019 (COVID-19) Reinfections, COVID-19 booster shots, Covid-19 Data, COVID-19 inoculations, COVID-19 Vaccines, Delta Variant (B.1.617.2; India), FDA, Pfizer
Pfizer and partner BioNTech plan to ask U.S. and European regulators within weeks to authorize a booster dose of the companies’ Covid-19 vaccine, based on evidence of greater risk of infection six months after inoculation and the spread of the highly contagious Delta variant.